Sinovac Awarded High-Tech Status, Which Brings Lower Taxes And Other Government Benefits
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Sinovac Biotech has been granted high-tech enterprise status by three government departments and will get a lower tax rate, at 15 percent, from the standard rate of 25 percent, from 2008 to 2010, the company announced March 9
You may also be interested in...
China Pharma Holdings Sees Increased Revenue From Sales Of Generic Version Of Bayer’s Aleve-D
SHANGHAI - China Pharma Holdings reported a 39 percent increase in net income to $17.8 million in 2008 due to a 76.6 percent increase in sales of its leading OTC cold and flu product PuSen OK (naprooxen and pseudophedrine), the only generic version in China of Bayer's Aleve-D
China Pharma Holdings Sees Increased Revenue From Sales Of Generic Version Of Bayer’s Aleve-D
SHANGHAI - China Pharma Holdings reported a 39 percent increase in net income to $17.8 million in 2008 due to a 76.6 percent increase in sales of its leading OTC cold and flu product PuSen OK (naprooxen and pseudophedrine), the only generic version in China of Bayer's Aleve-D
Sinovac To Start Clinical Trials For Hep A Vaccine In Ukraine; First Overseas Steps
SHANGHAI - Sinovac has inked a deal with Ukraine-based Biolik Biopharmaceutical to conduct clinical trials for its inactivated hepatitis A vaccine Healive in Ukraine, the company announced on Sept. 15